Dark
Light
Today: February 5, 2025
August 6, 2024
1 min read

Record-low year for Biotech VCs fundraising shows glimmers of recovery


TLDR:

  • Life science venture capital firms are experiencing record-low fundraising, potentially impacting startups
  • In the first half of the year, VC firms have raised only 15 pools of capital, down from previous years

Biotech VC firms are on track for another year of low fundraising, which may limit the funding available for startups in the coming years. In the first half of 2024, the industry has seen a decrease in the number of funds raised compared to previous years. Many VC firms are struggling post-COVID, grappling with inflated startup valuations and high levels of investment. While the stock market is recovering, the environment is challenging for biotechs. However, there are signs that the pressure is beginning to ease.


Previous Story

Nasir Qadree’s Inclusive Investing Vision at Zeal Capital Partners

Next Story

Wisconsin startup investments plummet after pandemic surge in 2023

Latest from Blog

VCFA Group Closes $1225M Venture Partners VII Fund

TLDR: VCFA Group closed VCFA Venture Partners VII fund with $122.5 million in commitments Transition marks continuation of VCFA’s pioneering legacy in the secondary private equity space VCFA Group, a pioneer in

Top AI Trends and Startups Shaping 2025 and Beyond

“`html TLDR: Israel is excelling in applicative and vertical AI, focusing on practical solutions in cybersecurity, healthcare, and defense rather than competing with tech giants in foundational AI models. Five key AI
Go toTop